Abstract:The rapid development of mRNA vaccines by Pfizer‐BioNTech and Moderna in 2020 was a significant milestone, overcoming mRNA instability and immunogenicity challenges. This paper reviews modifications enhancing mRNA stability and translation, but raises concerns about systemic biodistribution, unlimited Spike protein production, and serious adverse events. We emphasize the need for strategies to mitigate adverse effects, proposing small interfering RNA (siRNA) and ribonuclease targeting chimeras (RIBOTACs) as potential solutions to inactivate residual vaccine mRNA and prevent uncontrolled Spike protein production. This review calls for further research into these applications as antidotes and detoxication products for mRNA vaccine technology. The rapid development and authorization of messenger ribonucleic acid (mRNA) vaccines by Pfizer‐BioNTech (BNT162b2) and Moderna (mRNA‐1273) in 2020 marked a significant milestone in human mRNA product application, overcoming previous obstacles such as mRNA instability and immunogenicity. This paper reviews the strategic modifications incorporated into these vaccines to enhance mRNA stability and translation efficiency, such as the inclusion of nucleoside modifications and optimized mRNA design elements including the 5′ cap and poly(A) tail. We highlight emerging concerns regarding the wide systemic biodistribution of these mRNA vaccines leading to prolonged inflammatory responses and other safety concerns. The regulatory framework guiding the biodistribution studies is pivotal in assessing the safety profiles of new mRNA formulations in use today. The stability of mRNA vaccines, their pervasive distribution, and the longevity of the encapsulated mRNA along with unlimited production of the damaging and potentially lethal spike (S) protein call for strategies to mitigate potential adverse effects. Here, we explore the potential of small interfering RNA (siRNA) and ribonuclease targeting chimeras (RIBOTACs) as promising solutions to target, inactivate, and degrade residual and persistent vaccine mRNA, thereby potentially preventing uncontrolled S protein production and reducing toxicity. The targeted nature of siRNA and RIBOTACs allows for precise intervention, offering a path to prevent and mitigate adverse events of mRNA‐based therapies. This review calls for further research into siRNA and RIBOTAC applications as antidotes and detoxication products for mRNA vaccine technology.

Strategic deactivation of mRNA COVID‐19 vaccines: New applications for siRNA therapy and RIBOTACs

Strategies to reduce the risks of mRNA drug and vaccine toxicity

COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 2

Recent Advances in mRNA Vaccine Development

Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency

Next‐Generation Nonviral Vectors for Mrna Vaccine Delivery

Progress on Mrna Vaccines and Lipid Nanoparticles

Opportunities and Challenges for mRNA Delivery Nanoplatforms

Long‐lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID‐19 vaccination

Theoretical basis for stabilizing messenger RNA through secondary structure design

Synthetic modified messenger RNA for therapeutic applications

Engineered mRNAs With Stable Structures Minimize Double-stranded RNA Formation and Increase Protein Expression

The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics

Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety

Unlocking the potential of nanocarrier-mediated mRNA delivery across diverse biomedical frontiers: A comprehensive review

Polymer‐based mRNA delivery strategies for advanced therapies

Delivery Strategies for mRNA Vaccines

Effective Synthesis of mRNA during In Vitro Transcription with Fewer Impurities Produced

The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case

Unlocking the promise of mRNA therapeutics

Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations